CNR Institutional Research Information System

EVANGELISTI, CAMILLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 963
NA - Nord America 616
SA - Sud America 173
EU - Europa 145
AF - Africa 12
OC - Oceania 2
Totale 1.911
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 590
SG - Singapore 402
CN - Cina 248
BR - Brasile 149
VN - Vietnam 95
HK - Hong Kong 83
KR - Corea 47
FR - Francia 45
IT - Italia 31
IN - India 19
CA - Canada 16
JP - Giappone 13
AR - Argentina 11
BD - Bangladesh 11
DE - Germania 10
FI - Finlandia 10
NL - Olanda 10
IL - Israele 9
ES - Italia 7
IQ - Iraq 6
ZA - Sudafrica 6
CO - Colombia 5
EC - Ecuador 5
PL - Polonia 5
TR - Turchia 5
GB - Regno Unito 4
AE - Emirati Arabi Uniti 3
ID - Indonesia 3
IE - Irlanda 3
MX - Messico 3
PH - Filippine 3
SA - Arabia Saudita 3
AT - Austria 2
AU - Australia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
MA - Marocco 2
NP - Nepal 2
PE - Perù 2
RS - Serbia 2
SE - Svezia 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
EG - Egitto 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 1.911
Salva come PNG Salva come JPEG
Città #
Santa Clara 279
Singapore 231
Hefei 109
Hong Kong 80
San Jose 48
Seoul 47
Beijing 46
Lauterbourg 38
Ho Chi Minh City 37
Ashburn 35
Los Angeles 27
Hanoi 25
São Paulo 17
New York 16
Buffalo 10
Dallas 9
Helsinki 9
Rio de Janeiro 8
Minamishinagawa 6
Phoenix 6
Chennai 5
Da Nang 5
Houston 5
Orem 5
Baghdad 4
Bengaluru 4
Istanbul 4
Montreal 4
Tokyo 4
Warsaw 4
Boardman 3
Brooklyn 3
Curitiba 3
Dublin 3
Hải Dương 3
Newark 3
Quito 3
Toronto 3
Atlanta 2
Biên Hòa 2
Bogotá 2
Buenos Aires 2
Cape Town 2
Chicago 2
Chino 2
Colombo 2
Cà Mau 2
Denver 2
Feira de Santana 2
Frankfurt am Main 2
Goiânia 2
Hangzhou 2
Maceió 2
Modena 2
Mount Wolf 2
Nha Trang 2
Norristown 2
Nova Iguaçu 2
Nuremberg 2
Padova 2
Paracatu 2
Paris 2
Pilar 2
Pretoria 2
Salvador 2
San Francisco 2
Santos 2
Seattle 2
Shanghai 2
Staten Island 2
Thái Bình 2
Tucson 2
Venice 2
Zephyrhills 2
Zurich 2
'Asir Region 1
Abbottabad 1
Acalanes Ridge 1
Ahmedabad 1
Amarante 1
Amman 1
Ancol 1
Ankara 1
Anápolis 1
Aparecida d'Oeste 1
Araguaína 1
Arapiraca 1
Araras 1
Arari 1
Araxá 1
Arcoverde 1
Armilla 1
Athens 1
Atwater 1
Austin 1
Avondale 1
Balneário Camboriú 1
Baltimore 1
Barueri 1
Bauru 1
Totale 1.250
Salva come PNG Salva come JPEG
Nome #
Lamin A and Prelamin a Counteract Migration of Osteosarcoma Cells 101
The role played by wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia 90
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-?B. 78
Advances in targeting signal transduction pathways. 71
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. 69
Elevated TGF beta 2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 66
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 63
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. 58
Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 56
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 52
The emerging multiple roles of nuclear Akt. 51
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 50
Potential therapeutic effects of the mtor inhibitors for preventing ageing and progeria-related disorders. 48
The unfolded protein response: A novel therapeutic target in acute leukemias 48
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines 46
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 46
Therapeutic targeting of CK2 in acute and chronic leukemias 45
Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update 44
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 44
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. 43
GSK-3: a multifaceted player in acute leukemias 42
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 41
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. 38
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 37
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. 37
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 37
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 36
Targeting the cancer initiating cell: The ultimate target for cancer therapy 34
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 34
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. 34
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 33
Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway 32
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. 31
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: Targeting the unfolded protein response signaling 30
Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins 30
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 29
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 27
Autophagy in acute leukemias: A double-edged sword with important therapeutic implications 27
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mtor cascades which alter therapy response 26
Current treatment strategies for inhibiting mTOR in cancer 25
GSK-3beta: A key regulator of breast cancer drug resistance (Comment on: Sokolosky M, et al. Cell Cycle 2014; 13:820-33;) 25
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; Indications for novel therapeutics 24
DGKzeta is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. 23
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. 21
Totale 1.922
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.689
article - articoli 6.689
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.378
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20242 0 0 0 0 0 0 0 0 1 0 0 1
2024/2025783 6 4 56 27 233 56 11 49 23 9 153 156
2025/20261.104 72 111 86 228 176 46 150 46 49 73 26 41
2026/202733 33 0 0 0 0 0 0 0 0 0 0 0
Totale 1.922